Practical considerations and consensus opinion for children's hospital-based inpatient hemostasis and thrombosis (HAT) consultative services: Communication from the ISTH SSC Subcommittee on Pediatric/Neonatal Thrombosis and Hemostasis.
consultation
hemostasis
inpatient
pediatric
thromboembolism
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
26
05
2022
received:
25
03
2022
accepted:
19
06
2022
pubmed:
25
6
2022
medline:
17
8
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Caring for children and adolescents with disorders of hemostasis and thrombosis (HAT) has become more specialized and requires a unique skill set that many providers are not able to obtain in standard pediatric hematology/oncology/bone marrow transplant fellowship training programs. The influx of numerous therapeutic advances and increasing medical complexity has expanded the need for experienced HAT providers and subspecialty collaboration in the inpatient setting due to the nuances in the management of patients with HAT complications and concerns. While there are data highlighting the benefits of an inpatient hemostasis, thrombosis, and anticoagulation management service in adult hospitals, there are limited pediatric data supporting such programs. In this article, we summarize the current practices of various pediatric institutions in the inpatient management of HAT patients and provide a consensus opinion for the development of a pediatric inpatient HAT service at tertiary care referral centers.
Identifiants
pubmed: 35748322
doi: 10.1111/jth.15798
pii: S1538-7836(22)02108-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2151-2158Informations de copyright
© 2022 International Society on Thrombosis and Haemostasis.
Références
O'Brien SH, Stanek JR, Witmer CM, Raffini L. The continued rise of venous thromboembolism across US children's hospitals. Pediatrics. 2022;149:e2021054649.
Children's Hospitals' Solutions for Patient Safety Recommended Bundles: Adverse Drug Events - Venous Thromboembolism Version 3. Accessed November 04, 2021. http://www.solutionsforpatientsafety.org/wp-content/uploads/SPS-Recommended-Bundles.pdf.
Harrar DB, Benedetti GM, Jayakar A, et al. Pediatric acute stroke protocols in the United States and Canada. J Pediatr. 2021;242:220-227.e7.
Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26(5):601-608.
Fanikos J, Stapinski C, Koo S, Kucher N, Tsilimingras K, Goldhaber SZ. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol. 2004;94(4):532-535.
The Joint Commission, National patient safety goals NPSG 03.05.01. Accessed November 11, 2021. https://www.jointcommission.org/-/media/tjc/newsletters/cah_doac_prepub_jul2019pdf.pdf?db=web&hash=D146335334375FF624A8FC235E89E629&hash=D146335334375FF624A8FC235E89E629.
Lee T, Davis E, Kielly J. Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature. Integr Pharm Res Pract. 2016;5:53-63.
Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood. 2000;96(2):437-442.
Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004;127(4):379-391.
Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
Mancuso ME, Mahlangu J, Sidonio R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-results from the HAVEN 2 study. Haemophilia. 2020;26(6):1009-1018.
Fontana P, Alberio L, Albisetti M, et al. Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. Swiss Med Wkly. 2020;150:w20422.
Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384-1393.
Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004;24(8):953-963.
Wong YM, Quek YN, Tay JC, Chadachan V, Lee HK. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration. J Clin Pharm Ther. 2011;36(5):585-591.
Biscup-Horn PJ, Streiff MB, Ulbrich TR, Nesbit TW, Shermock KM. Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother. 2008;42(6):777-782.
Reardon DP, Atay JK, Ashley SW, Churchill WW, Berliner N, Connors JM. Implementation of a hemostatic and antithrombotic stewardship program. J Thromb Thrombolysis. 2015;40(3):379-382.
Schillig J, Kaatz S, Hudson M, Krol GD, Szandzik EG, Kalus JS. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011;6(6):322-328.
Oldenburg J, Levy GG. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(22):2194-2195.
Karkouti K, Arellano R, Aye T, et al. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report). Can J Anaesth. 2014;61(8):727-735.
Todd RF, Gitlin SD, Burns LJ, Programs COT. Subspeciality training in hematology and oncology, 2003: results of a survey of training program directors conducted by the American society of hematology. Blood. 2004;103(12):4383-4388.
Berntorp E, Gomperts E, Hoots K, Wong WY. The next generation of hemophilia treatment specialists. Semin Thromb Hemost. 2006;32(Suppl 2):39-42.
Thornburg CD, Montgomery RR, Pipe SW. How we approach: training pediatric coagulationists. Pediatr Blood Cancer. 2019;66(12):e27982.
Attia E, Fuentes A, Vassallo M, Dobbs S, Nguyen P, Baker K. Establishing a multidisciplinary taskforce to improve anticoagulation safety at a large health system. Am J Health Syst Pharm. 2022;79(4):297-305.
Burnett A, D'Angio R, Earl LE, Garcia D. Challenges and benefits of an inpatient anticoagulation service: one hospital's experience. J Thromb Thrombolysis. 2011;31(3):344-352.
Anticoagulation Forum, Core Elements of Anticoagulation Stewardship Programs, 2019. Accessed January 05, 2022. https://acforum-excellence.org/Resource-Center/resource_files/-2019-09-18-110254.pdf.
Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. Ann Pharmacother. 2013;47(5):714-724.
Ross C, Kumar R, Pelland-Marcotte MC, et al. Acute management of high-risk and intermediate-risk pulmonary embolism in children: a review. Chest. 2022;161(3):791-802.
Tully MP, Ashcroft DM, Dornan T, Lewis PJ, Taylor D, Wass V. The causes of and factors associated with prescribing errors in hospital inpatients: a systematic review. Drug Saf. 2009;32(10):819-836.
Kripalani S, Theobald CN, Anctil B, Vasilevskis EE. Reducing hospital readmission rates: current strategies and future directions. Annu Rev Med. 2014;65:471-485.
Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP guidelines on preventing medication errors in hospitals. Am J Health Syst Pharm. 2018;75(19):1493-1517.
DeSancho M, Munn JE, Billett HH, et al. Transition of care for pediatric and adult patients with venous thromboembolism: a national quality improvement project from the American thrombosis and hemostasis network (ATHN). Thromb Res. 2021;200:23-29.
Garcia DA, Schwartz MJ. Warfarin therapy: tips and tools for better control. J Fam Pract. 2011;60(2):70-75.